Tiziana Life Sciences is trading at $1.03, up 5.05% in after-hours trading; available reporting does not establish a cause for the move. - On September 28, Tiziana announced that the first three participants received doses in its Phase 2a BANYAN ALS trial of intranasal foralumab. - The broader market was down, so the supplied context does not indicate a same-direction market explanation. - No verified after-hours volume or activity details were available.